全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Primary Systemic Al Amyloidosis Presenting as Temporal Arteritis

DOI: 10.1155/2014/549641

Full-Text   Cite this paper   Add to My Lib

Abstract:

Temporal arteritis is most common vasculitis in elderly and imitated by miscellaneous disorders. Temporal artery biopsy is the gold standard test in the diagnosis of giant cell arteritis (GCA). Hereby, we describe a case of a 67-year-old man who presented initially with temporal arteritis; however, a lip biopsy then revealed AL amyloidosis. In this respect, temporal artery biopsy should be performed for definitive diagnosis of GCA particularly patients with systemic symptoms and treatment resistant. 1. Primary Systemic Al Amyloidosis Presenting with Temporal Arteritis Giant cell arteritis (GCA), also called temporal arteritis, is a vasculitis that affects large-and middle-sized blood vessels in individuals older than 50 years of age. A temporal artery biopsy (TAB) is the gold standard test in the diagnosis of GCA [1]. Because corticosteroid therapy is required for more than 1 year in most cases, the pathological confirmation of this vasculitis is advisable. AL amyloidosis is a systemic disorder that can present with a variety of symptoms or signs, including heavy proteinuria, edema, hepatosplenomegaly, otherwise, unexplained heart failure, and the carpal tunnel syndrome [2]. It often requires high clinical suspicion because symptoms are miscellaneous and easily mimicked by more common disorders. Hereby, we describe a case of a 67-year-old man who presented initially with GCA; however, a minor salivary gland biopsy then revealed AL amyloidosis. Hence, temporal artery biopsy should be performed for definitive diagnosis of temporal arteritis. 2. Case Report A 67-year-old man was applied to our hospital with a one-year history of weakness, fatigue, headache, extremity, and jaw claudication. Two months earlier he developed bilateral lack of vision and diagnosed ischemic optic neuropathy by ophthalmologist and hence started high dose corticosteroid treatment. Eye findings were improved by this treatment. On examination, the patient appeared well and his vital signs were normal. The temporal arteries were noted to be thickened, nodular, and decreased pulsation (Figure 1). Temporal arteritis was considered because of these findings and methotrexate was added to the patient therapy. Temporal artery biopsy was not considered in consequence of receiving corticosteroid therapy for two months. Figure 1: (a) Macroglossia due to amyloidosis and (b) enlarged and nodular temporal artery. During the followup, just after corticosteroid dose reduced, the patient was hospitalized to reevaluate because of recurrent complaints of increasing difficulty in walking,

References

[1]  M. A. Gonzalez-Gay, “The diagnosis and management of patients with giant cell arteritis,” Journal of Rheumatology, vol. 32, no. 7, pp. 1186–1188, 2005.
[2]  M. Rosenzweig and H. Landau, “Light chain (AL) amyloidosis: update on diagnosis and management,” Journal of Hematology and Oncology, vol. 4, article 47, 2011.
[3]  A. Bhat, C. Selmi, S. M. Naguwa, G. S. Cheema, and M. E. Gershwin, “Currents concepts on the immunopathology of amyloidosis,” Clinical Reviews in Allergy and Immunology, vol. 38, no. 2-3, pp. 97–106, 2010.
[4]  R. H. Falk, R. L. Comenzo, and M. Skinner, “The systemic amyloidoses,” The New England Journal of Medicine, vol. 337, no. 13, pp. 898–909, 1997.
[5]  R. A. Kyle and M. A. Gertz, “Primary systemic amyloidosis: clinical and laboratory features in 474 cases,” Seminars in Hematology, vol. 32, no. 1, pp. 45–59, 1995.
[6]  P. Lafforgue, E. Senbel, D. Figarella-Branger et al., “Systemic amyloidosis AL with temporal artery involvement revealing lymphoplasmacytic malignancy in a man presenting as polymyalgia rheumatica,” Annals of the Rheumatic Diseases, vol. 52, no. 2, pp. 158–160, 1993.
[7]  C. Salvarani, S. E. Gabriel, M. A. Gertz, J. Bjornsson, C.-Y. Li, and G. G. Hunder, “Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica,” Arthritis and Rheumatism, vol. 37, no. 11, pp. 1621–1626, 1994.
[8]  C. H. Churchill, A. Abril, M. Krishna, M. L. Callman, and W. W. Ginsburg, “Jaw claudication in primary amyloidosis: unusual presentation of a rare disease,” Journal of Rheumatology, vol. 30, no. 10, pp. 2283–2286, 2003.
[9]  A. Estrada, T. T. Stenzel, J. L. Burchette, and N. B. Allen, “Multiple myeloma-associated amyloidosis and giant cell arteritis,” Arthritis and Rheumatism, vol. 41, pp. 1312–1317, 1998.
[10]  W. A. Schmidt and E. Gromnica-Ihle, “Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries,” Rheumatology, vol. 41, no. 1, pp. 46–52, 2002.
[11]  T. A. Bley, M. Markl, M. Schelp et al., “Mural inflammatory hyperenhancement in MRI of giant cell (temporal) arteritis resolves under corticosteroid treatment,” Rheumatology, vol. 47, no. 1, pp. 65–67, 2008.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133